BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.

XOMA Corporation announced it entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc..

Anavex Life Sciences Corp. announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agency’s centralised procedure.

Repligen Corporation today announced that it will present at the 42nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. Tony J. Hunt, Chief Executive Officer, will present an overview of the company on Tuesday, January 9, 2024, at 2:15 p.m. PST.

Harpoon Therapeutics, Inc. today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

Ocugen, Inc. today announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations.

Zimmer Biomet Holdings, Inc. today announced that members of the Zimmer Biomet management team will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 , at 8:15 a.m. PT ( 11:15 a.m. ET ).

Trinity Capital Inc. today announced the commitment of $40 million in term loans to Taysha Gene Therapies, Inc.

Syros Pharmaceuticals announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024.